Abstract
<b><i>Objective:</i></b> Follicle-stimulating hormone (FSH) level changes may be another reason for increasing the risk of cardiovascular disease. In this study, we aimed to investigate the role of FSH in atherosclerosis and its underlying mechanism. <b><i>Methods:</i></b> ApoE<sup>−/−</sup> mice were divided into 4 groups, namely, the sham group, bilaterally orchidectomized group, FSH group, and testosterone-only group. Blood lipid and hormone levels were tested, aorta Oil Red O staining; the levels of NF-κB, Akt, eNOS, and FSH receptors in the aorta were measured by Western blotting. Expression of VCAM-1 was detected via Western blotting and immunohistochemical staining. Human umbilical vein endothelial cells (HUVECs) were used to induce endothelial injury model by adding FSH, and the levels of NF-κB, Akt, eNOS, and FSHR were tested in HUVECs. <b><i>Results:</i></b> FSH treatment exacerbated atherosclerotic lesions in ApoE<sup>−/−</sup> mice. Moreover, FSH could promote the expression of VCAM-1 protein in HUVECs, and this effect was possibly mediated by the activation of NF-κB, while NF-κB activation was further enhanced by the activation of the PI3K/Akt/eNOS pathway. FSH failed to activate Akt and NF-κB in the presence of the PI3K inhibitor LY294002 in HUVECs. <b><i>Conclusion:</i></b> FSH promoted the development of atherosclerosis by increasing VCAM-1 protein expression via activating PI3K/Akt/NF-κB pathway.
Subject
Cardiology and Cardiovascular Medicine,Physiology
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Hydroxysafflor yellow A, a natural food pigment, ameliorates atherosclerosis in ApoE−/− mice by inhibiting the SphK1/S1P/S1PR3 pathway;Food Science & Nutrition;2024-09-14
2. Follicle-stimulating hormone receptor expression in advanced atherosclerotic plaques;Scientific Reports;2024-05-03
3. FSH, bone, belly and brain;Journal of Endocrinology;2024-04-03
4. FSH Is Responsible for Androgen Deprivation Therapy–Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-03
5. Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open‐label, phase 2 trial;The Prostate;2024-02-04